RxDoctor Payments DataLook up a doctor →

Murthy Vuppala, MD

Pulmonary Disease · Huntsville, ALNPI 1093762346

Payments from drug & device makers

$15,811in general payments, 2019–2025

Across 768 payments — averaging $20.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • GSK$3K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Boehringer Ingelheim$1K
  • Sanofi$726
  • Insmed, Inc.$708
  • plus $6K from 41 others

What the payments were for

  • Food & beverage$15,55598%
  • Education$2552%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,811 in reported general payments places this provider in the 80th percentile of 215 pulmonary disease providers in Alabama.

See all pulmonary disease providers in Alabama

Medicare billing

Part B allowed, 2024
$671,122
Medicare patients
1,129
Services billed
10,940

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter368$292,819
OfevNintedanib Esylate13$169,340
Breztri AerosphereBudesonide/Glycopyr/Formoterol76$53,751
Breo ElliptaFluticasone/Vilanterol91$48,366
XolairOmalizumab14$47,693
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr69$37,068
Fluticasone-SalmeterolFluticasone Propion/Salmeterol102$24,296
Spiriva RespimatTiotropium Bromide23$21,206
SymbicortBudesonide/Formoterol Fumarate63$20,868
Advair HfaFluticasone Propion/Salmeterol56$19,845
Stiolto RespimatTiotropium Br/Olodaterol Hcl23$15,831
Combivent RespimatIpratropium/Albuterol Sulfate30$14,743
DuleraMometasone/Formoterol26$11,020
Tiotropium Bromide16$9,302
Incruse ElliptaUmeclidinium Bromide11$6,543

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$2,844$384,796539 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$1,232$221,12089 claims
AstraZenecaBreztri Aerosphere, Symbicort$3,004$74,619139 claims
MerckDulera$242$11,02026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 215 pulmonary disease providers in Alabama.

Other pulmonary disease in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →